Abstract: “The term “personalized medicine” has been generated to indicate strategies for targetting medical treatments in each individual patient based on his/her own phenotype, genotype, lifestyle, and clinical records. Initially, these strategies were largely based on classical pharmacogenetic and pharmacogenomic methodologies. Later on this concept became progressively wider and included further predictive genomics approaches enabling patient stratifications based upon genetic risk to develop specific diseases. Indeed, improved understanding of human genome brought personalized medicine into the novel dimension of “predictive medicine” which enables quantitation of disease risk in addition to disease presence. The legal, bioethical and socio-economic implications of this advancement have only recently started to attract interest on how to compromise the need of scientific progress and the protection of the fundamental rights both at the individual and at the community levels. This is clearly”

Keywords: genetic data, personalized medicine, insurance contracts, legislation